Assyro AI

Orange Book product · Brand (NDA)

AKYNZEO

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

Brand (NDA)NDA 210493DISCN HELSINN HLTHCARE

At a glance

Apr 19, 2018

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Apr 19, 2018

    8 yr 3 mo ago

  2. Today

  3. Patent 9186357 expires

    Listed method-of-use patent (U-2301) expiration.

    Nov 18, 2030

    in 4 yr 6 mo

  4. Patent 10828297 expires

    Listed method-of-use patent (U-2301) expiration.

    Dec 17, 2030

    in 4 yr 7 mo

  5. Patent 10208073 expires

    Listed method-of-use patent (U-2301) expiration.

    May 23, 2032

    in 6 yr

  6. Patent 10717721 expires

    Listed drug substance patent expiration.

    May 23, 2032

    in 6 yr

  7. Patent 11312698 expires

    Listed drug substance patent expiration.

    May 23, 2032

    in 6 yr

  8. Patent 8426450 expires

    Listed drug substance patent expiration.

    May 23, 2032

    in 6 yr

  9. Patent 8895586 expires

    Listed method-of-use patent (U-2301) expiration.

    May 23, 2032

    in 6 yr

  10. Patent 9403772 expires

    Listed drug substance patent expiration.

    May 23, 2032

    in 6 yr

  11. Patent 9908907 expires

    Listed drug substance patent expiration.

    May 23, 2032

    in 6 yr

  12. Patent 10624911 expires

    Listed drug product patent expiration.

    Jun 02, 2037

    in 11 yr 1 mo

  13. Patent 11529362 expires

    Listed drug product patent expiration.

    Jun 02, 2037

    in 11 yr 1 mo

  14. Patent 12208109 expires

    Listed drug product patent expiration.

    Jun 02, 2037

    in 11 yr 1 mo

Pharmaceutical detail

Active ingredient

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

Strength

EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 210493

Product number

001

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9186357Nov 18, 2030in 4 yr 6 mo
U-2301
10828297Dec 17, 2030in 4 yr 7 mo
U-2301
10208073May 23, 2032in 6 yr
U-2301
10717721May 23, 2032in 6 yr
Substance
11312698May 23, 2032in 6 yr
SubstanceProduct
8426450May 23, 2032in 6 yr
SubstanceProduct
8895586May 23, 2032in 6 yr
U-2301
9403772May 23, 2032in 6 yr
SubstanceU-2301
9908907May 23, 2032in 6 yr
SubstanceProduct
10624911Jun 02, 2037in 11 yr 1 mo
Product
11529362Jun 02, 2037in 11 yr 1 mo
Product
12208109Jun 02, 2037in 11 yr 1 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.